Haleon plc (HLN.L)

LSE · Healthcare · Drug Manufacturers - Specialty & Generic
345.30 GBp+0.99%As of 2026-11-22 · GBp
Last session low 344.80 GBpLast session high 348.90 GBp
52-week low 310.50 GBp52-week high 433.60 GBp
Market cap (USD)
$39.60B
Sector
Healthcare
P/E (TTM)
19.2x
Dividend yield
2.11%

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in GBp.

IndicatorValueReading
RSI (14)50.1In the neutral range (30 to 70)
MACD (12, 26, 9)-2.28Above its signal line (-3.13); histogram 0.85
Bollinger %B (20, 2)54%Inside the bands (308.47 to 376.59)
SMA 20342.53Price is 0.8% above
SMA 50347.07Price is 0.5% below
SMA 200357.07Price is 3.3% below
ATR (20)2.70% of priceAverage true range per day
52-week position28%In the lower part of the 310.50 to 433.60 range

About Haleon plc

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Insider filings, 90 days4 purchases (about 101K GBP) and no sales.
Latest fiscal yearEnded 2025-12-31: revenue of 11.03B GBP and an operating margin of 21.9%.

Also listed as HLN (NYSE)

More in Drug Manufacturers - Specialty & Generic